Vertex Pharmaceuticals

477.51
2.95 (0.62%)
At close: Apr 08, 2025, 2:14 PM

Vertex Pharmaceuticals Revenue Breakdown

Period Ending Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020
TRIKAFTA/KAFTRIO Revenue 2.58B 2.45B 2.48B 2.33B 2.27B 2.24B 2.1B 2.02B 2.01B 1.89B 1.76B 1.69B 1.56B 1.26B 1.19B 960.31M 917.72M 895.23M
TRIKAFTA/KAFTRIO Revenue Growth +5.54% -1.39% +6.44% +2.59% +1.51% +6.85% +3.72% +0.55% +6.20% +7.47% +4.08% +8.79% +23.91% +5.23% +24.25% +4.64% +2.51% n/a

Revenue by Geography

Period Ending Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020 Dec 31, 2019 Dec 31, 2018 Dec 31, 2017 Dec 31, 2016 Dec 31, 2015 Dec 31, 2014 Dec 31, 2013 Dec 31, 2012 Dec 31, 2011
Europe Revenue 3.11B 2.71B 1.97B 1.13B 885.76M 543.18M 420.32M 320.46M 219.6M 197.61M 279.56M 1.37B 1.39B
Europe Revenue Growth +14.91% +37.13% +75.14% +27.17% +63.07% +29.23% +31.16% +45.93% +11.13% -29.31% -79.65% -1.16% n/a
Non-Us Revenue 4.55B 3.76B 2.6B 1.63B 1.31B 821.86M 501.87M 380.37M 269.02M 219.34M 315.02M n/a n/a
Non-Us Revenue Growth +21.06% +44.55% +59.82% +23.70% +59.98% +63.76% +31.94% +41.39% +22.65% -30.37% n/a n/a n/a
United States Revenue 6.04B 5.7B 5.29B 4.83B 3.06B 2.37B 1.99B 1.32B 763.32M 361.07M 896.95M n/a n/a
United States Revenue Growth +5.98% +7.79% +9.48% +57.69% +29.49% +19.04% +50.31% +73.17% +111.40% -59.74% n/a n/a n/a

Operating Expense Breakdown

Period Ending Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018 Dec 31, 2017 Sep 30, 2017 Jun 30, 2017 Mar 31, 2017 Dec 31, 2016 Sep 30, 2016 Jun 30, 2016 Mar 31, 2016 Dec 31, 2015 Sep 30, 2015 Jun 30, 2015 Mar 31, 2015
Selling, General, and Administrative Revenue 377.6M 371.8M 372.2M 342.7M 369.1M 263.8M 262.6M 241.1M 267.4M 246.8M 215.3M 215.2M 255.2M 198.19M 194.67M 192.08M 211.84M 184.55M 191.8M 182.26M 195.28M 159.67M 156.5M 147.04M 153.21M 137.29M 137.3M 129.81M 134.79M 120.71M 127.25M 113.33M 109.91M 106.06M 111.65M 105.21M 97.05M 99.77M 94.39M 85.86M
Selling, General, and Administrative Revenue Growth +1.56% -0.11% +8.61% -7.15% +39.92% +0.46% +8.92% -9.84% +8.35% +14.63% +0.05% -15.67% +28.77% +1.81% +1.35% -9.33% +14.79% -3.78% +5.24% -6.67% +22.30% +2.03% +6.43% -4.02% +11.59% -0.01% +5.77% -3.70% +11.67% -5.14% +12.29% +3.11% +3.63% -5.01% +6.12% +8.41% -2.72% +5.70% +9.94% n/a
Research and Development Revenue 998.7M 875.9M 5.42B 865.9M 821.8M 810M 785.7M 742.6M 694.1M 645M 600.1M 603.1M 694.3M 493.75M 1.41B 455.97M 466.58M 493.5M 420.93M 448.53M 480.01M 555.95M 379.09M 339.49M 437.88M 330.51M 337.53M 310.55M 306.66M 454.95M 289.45M 273.56M 248.45M 275.37M 271.01M 255.86M 310.43M 246.28M 223.86M 215.6M
Research and Development Revenue Growth +14.02% -83.83% +525.44% +5.37% +1.46% +3.09% +5.80% +6.99% +7.61% +7.48% -0.50% -13.14% +40.62% -64.91% +208.59% -2.27% -5.45% +17.24% -6.15% -6.56% -13.66% +46.65% +11.66% -22.47% +32.49% -2.08% +8.69% +1.27% -32.59% +57.18% +5.81% +10.11% -9.78% +1.61% +5.92% -17.58% +26.05% +10.02% +3.83% n/a